65,437 trials
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of L-Praziquantel…
Patients With Hemophilia
Primary: Changes in Range of Motion of Elbow — 138.31; 136.13; 138.00; 135.56 degrees
Infections, Rotavirus
Primary: Number of Seroconverted Subjects Against Human Rotavirus — 363; 319 Subjects
Schizophrenia
Primary: Safety and Tolerability — 337 TEAEs
Arthritis · Rheumatoid
Primary: Number of Participants With Treatment Related Adverse Events — 2 participants
Anemia, Aplastic · Anemia, Hypoplastic
Primary: Number of Participants With Complete Response at 3 Months. — 0 Participants
Diabetic Macular Edema
Primary: The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months — 0; 0.53 ETDRS letters
Premature Birth
Primary: Parent Child Interaction Teaching Scale (PCITS) — 40.00; 41.61; 38.83; 9.26 Scores on a scale — p==0.03
Myopia
Primary: Lens Fit - Centration — 48; 46; 4; 6 participants
Norovirus Prevention
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection — 7.8; 64.1; 72.7; 7.8 percentage of participants
Gynecologic Tumors
Primary: Dose Limiting Toxicity (DLT) — 8; 23; 2 participants
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Psoriasis
Primary: The Percentage of Lesions With a Clear or Almost Clear Rating (Target Lesion Score of 3 or Less) on Target Lesion Scoring at Week 12 — 47.6; 33.3 percentage of lesions…
Multiple Myeloma
Primary: Number of Participants With Hematologic Response — 7 participants
Neoplasms
Primary: AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for…